Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.50 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.50 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20739971 | 0.95 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL20739965 | 0.93 | MAPT (0.49) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL7293667 | 0.91 | MAPT (0.49) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL7436582 | 0.88 | THRA (0.50) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL7999552 | 0.87 | PPARD (0.60) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL919038 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL3023099 | 0.86 | THRA (0.48) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL3027255 | 0.86 | THRA (0.51) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL3199017 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D | |
| SCHEMBL7855263 | 0.85 | THRA (0.50) | CYP1A2CYP2C9CYP2C19CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2644599-A1 | Method for preparing 1-substituted-4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-05-24 | — | — | US | disclosed |
| US-8129544-B2 | Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7807843-B2 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-08-21 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| CN-1326840-C | 1-substituted-4-nitroimidazole compounds and process for preparing same | OTSUKA PHARMA CO LTD (JP) | 2007-07-18 | — | — | CN | disclosed |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| CN-1692103-A | 1-substituted-4-nitroimidazole compounds and process for preparing same | OTSUKA PHARMA CO LTD (JP) | 2005-11-02 | — | — | CN | disclosed |
| EP-1553088-A1 | 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Otsuka Pharmaceutical Company, Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-4298739-A | ANTICOAGULANTS, ANTIINFLAMMATORY, ANTIULCER, VASODILATOR, PHOSPHODIESTERASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | CBR1, CBR3, DCXR | CYP1A2 220/4885CYP2C9 179/4885CYP2C19 207/4885 |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | CBR1, CBR3, DCXR | CYP1A2 185/4885CYP2C9 146/4885CYP2C19 191/4885 |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | CYP1A2 220/4885CYP2C9 179/4885CYP2C19 207/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | CYP1A2 220/4885CYP2C9 179/4885CYP2C19 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.